Wednesday, 14th November Clinical Oncology Society of Australia Annual Scientific Meeting 2018

In 2018, we are seeing still seeing patients diagnosed with mesothelioma. In fact, the numbers continue to remain steady. Asbestos was taken out of building products in 1983 and banned from most work sites in the late 70"s. If we've been efficient in eradicating asbestos, then why are we still experiencing disease. We still have end user exposures, asbestos in buildings and products imported containing asbestos. Exposure continues to occur today. The purpose of this presentation is to discuss the legal ramifications of 3rd wave or in-situte exposures. We will be addressing the complex legal causation issues that such cases throw up together with imported products.

Chair: TBC

Speaker: Jonathan Walsh, Principal Lawyer, Maurice Blackburn

This breakfast session is supported by COSA

Description: All members of the multidisciplinary team are encouraged to join us for this informative and interactive breakfast session. Cancer malnutrition is a significant issue for our patients with a substantial impact on quality of life and outcomes. Our speakers will discuss the latest research and strategies for multidisciplinary management of malnutrition.

Speaker: Prof Marian de van der Schueren, Prof Stephen Clarke, Jane Stewart

This breakfast session is supported by COSA

It is with great pleasure that we invite you all to this year’s Ipsen sponsored symposium – “N.E.T – Connecting the Last 110 Years” – from when Siegfried Orberndorfer first coined the term ‘karzinoide’ for what we now refer to as neuroendocrine tumours (NETs). This screening will take you back in time to 1907, on a journey through the last 110 years of NETs history, focusing on scientific discoveries, diagnostic advances and treatment developments, all of which have contributed to optimising patient care. At pivotal points of the film, our expert faculty will offer insight and opinion on the innovations and collaborations that have led to improvements in patient care over the past century. 

Join us and take your seats to enjoy learning about how the past can help to shape the future.

• The Western Australian cancer single cell initiative - Alistair R Forrest
• Integrating genetic and genomic testing into the routine pathology workflow - Benhur Amanuel
• Genomics directed clinical trials - Dean Fennell
• The NOMINATOR Trial – panel testing in the Australian Context - Clare Scott

Panel discussion at end

• Nutritional interventions in patients with cancer - Marian A.E. de van der Schueren
• International nutrition audit in foregut tumours (INFORM): an exploration of nutrition care processes in cancer care settings - Judy Bauer
• Nutritional impact of a gastroenteropancreatic neuroendocrine tumour from a patient's perspective - Erin Laing
• Malnutrition and sarcopenia in patients with malignant pleural mesothelioma - Emily Jeffery

• Exposure and burden of disease related to occupational carcinogens - Tim Driscoll
• Asbestos-Related Diseases in the Global Context - Ken Takahashi
• Regulatory compliance – why it is not enough to protect the health of workers. - Robert McDonald
• Occupational cancer and compensation - the legislative aspects    - Simon Millman
• Occupational (Lung) Cancers and Compensation - Euan Thompson

• Development of integrated Phase I trials in a Comprehensive Cancer Centre - Jayesh Desai
• The Oncology Phase I unit at Linear Clinical Research - Zelda Herbst
• Outcomes of patients going through trials at a phase 1 clinical trials unit - Mihitha Ariyapperuma

Panel discussion at the end

• Understanding underuse of surgery for early non-small cell lung cancer – contribution of enhanced comorbidity ascertainment from population-level hospital and pharmaceutical dispensing data - Nicola Creighton
• A risk prediction model for the development of subsequent primary melanoma in a population-based cohort   - Anne E Cust
• Patterns of comorbidities in women with breast cancer: a Canadian population-based study - Huah Shin Ng
• Large-scale systematic analysis of relationships between cancer risk factors and their joint association with cancer incidence - Julia Steinberg
• Influence of remoteness of residence on timeliness of diagnosis and treatment, and survival of patients with head and neck cancer in New South Wales, Australia - Rebecca L Venchiarutti

11:00am Haryana Dhillon – Introduction

• Implementation of Digital Technology in Cancer Care: What Can We Learn From Published Evidence? - Bogda Koczwara
• ADAPTing distress screening to local settings: how are we doing this? - Phyllis Butow
• It’s a long road to “business as usual”: Where to for the PROMPT-Care eHealth system? - Afaf Girgis
• 'If we build it will they really come’: what is needed to implement sustainable e-Health systems - Joanne Shaw

Panel discussion

This session follows a highly successful format used at previous meetings. It is designed to provide a forum for discussion of the complex issues which arise in the care of patients with mesothelioma and colorectal cancer. The chairs will present a series of challenging clinical cases and engage members of the multidisciplinary panel in discussion. There will also be opportunities for members of the audience to contribute to the discussion.

Case 1: Early mesothelioma
Panel:

• Caitlin Broderick – Nurse
• John Edwards - Thoracic surgeon
• Dean Fennell - Medical oncologist 
• Gary Lee - Respiratory physician 
• Kenneth Lee – Pathologist
• Mo Mo Tin - Radiation oncologist

Case 2: Management of rectal cancer and concurrent liver mets

Panel:

• Dirk Arnold - Medical oncologist (sponsored by Merck)
• Mayank Bhandari - Liver surgeon 
• Chris Hemmings - Pathologist
• Theodore Hong - Radiation oncologist 
• Nicole Newell – Nurse
• Cameron Platell - Surgeon

• Decreased cancer cell-surface urokinase plasminogen activator receptor (uPAR) negates several hallmarks of cancer - Abidali Mohamedali
• Young cancer patient perspectives on undertaking whole genome sequencing: A qualitative study - Nicole Bartley
• A New Fluorescence-targeted Tracer for Sentinel Lymph Node Biopsy - Bin-Bin Cong
• The decision-making process in adolescents and young adults with cancer and their families: a systematic review - Danielle Gessler
• Development of a Quality Framework for Cancer Multidisciplinary Team meetings in Victoria - Mwila Kabwe
• Radiomic analysis using Contrast-Enhanced CT: predict treatment response to pulsed low dose rate radiotherapy in gastric carcinoma with peritoneal cavity metastasis - Zhen Hou
• Measuring what’s important to our patients: The Continuous Improvement in Care - Cancer (CIC Cancer) Project - Angela Ives
• Translational Medicine - the uptake of pan-cancer panel testing in Australia - Matt Johnson
• CD4/CD8 ratio correlates with lymph node involvement in patients with oral cavity squamous cell carcinoma. - Shaun Liow
• Optimising sub-regional nurse-led oncology services supported by outreach through action research planning - Mwila Kabwe
• Applying implementation science principles to Optimal Cancer Care within primary health at scale - Sue M Merritt
• Validation of the Prognostic and Predictive Value of the Cancer Stem-Like Cell Marker SOX2 in Colorectal Cancer - Tim J Miller
• Tumour-derived extracellular vesicles (EV) – a real time functional assessment of tumour activity in patients with head and neck cancer (HNC). - Bella Nguyen
• Prognostic utility of CDX2 and PD-L1 in Rectal Cancer - Bella Nguyen
• Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors (AUTO-CHECK study) - Anna K Nowak
• Accurate Measurement of Tumor Mutation Burden Through Tumor-Only Sequencing Using a 500-Gene Panel - Joel Geoghegan
• RIPK1 binds MCU to mediate induction of mitochondrial Ca²⁺ uptake and promote colorectal oncogenesis - Fanxin Zeng
• The cost effectiveness of primary versus secondary prophylaxis with pegylated G-CSF to prevent hospitalization due to febrile neutropenia amongst early breast cancer patients. - Afaf Abed
• Definitive chemoradiotherapy for stage II-III non-small cell lung cancer: Patient outcomes in South Western Sydney Local Health District      - Tamiem Adam
• Cisplatin and Vinorelbine with Radiotherapy for local advanced non-small cell lung cancer – how good is it? - Anas Alawawdeh
• Conducting early-phase oncology clinical trials: experience of a dedicated clinical trial unit - Belinda Bahari
• Adherence to antibiotic guidelines in the management of febrile neutropenia - Tim Ball
• PD1 inhibitors and endocrine dysfunction: patterns and outcomes - Amy Body
• ‘Is the bar high enough’ A review of pre-clinical and clinical evidence used for phase 3 trials in castrate resistant prostate carcinoma. - Emma Carson
• Cardiotoxicity in advanced HER2 positive breast cancer in real world Australian patients receiving HER2-targeted therapy in the first-line setting - Rossa King
• Attitudes to Inferior Vena Cava Filters (IVCFs) among Medical Oncologists, Haematologists and Respiratory Physicians - Philip Craven
• Review of the integrated exercise physiology (EP) clinic at a tertiary cancer centre: experience from the Adem Crosby Centre, Sunshine Coast University Hospital (SCUH). - James Fletcher
• Clinical implementation of personalised medicine for 6 high priority WA cancers - Tim Humphries
• Remaining financially viable in the clinical trials industry requires the skill set of Harry Houdini - Fiona Jonker
• Exploring Head and Neck Cancer Patients’ Experiences with Radiation Therapy Immobilisation Masks: a qualitative study - Rachael M Keast
• Prediction of recurrence and survival using PET SUV Max in patients with resected non-small cell lung cancer - Wei-Sen Lam
• Afatinib for patients with EGFR mutation-positive (EGFRm+) NSCLC: activity in patients with baseline brain metastases and impact on the rate of central nervous system (CNS) progression or spread - Angela Maerten
• Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: experience in ‘real-world’ clinical practice - Angela Maerten
• Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC) in a real-world setting - Angela Maerten
• Multi-centre, Randomised, Double-blind, Placebo-controlled Trial of Additive Duloxetine for Cancer-related Neuropathic Pain Refractory to Opioids and Gabapentinoids - Hiromichi Matsuoka
• Standardising the measurement of cancer patient experience in Queensland: a feasibility study - Peter McGuire
• Utilising non-admitted code sets for an Outpatient cancer patient experience survey - Peter McGuire
• Dexamethasone and Obesity-related complications amongst patients with Glioblastoma; a retrospective review of a single tertiary center. - Michelle McMullen
• Phase 1 study of NOX66 in combination with Carboplatin in patients with end stage solid tumours - Marinella Messina
• A case of neuropsychiatric and neurological sequelae of severe radionecrosis of the corpus callosum following cyber-knife radiotherapy in a young female patient treated for metastatic melanoma - Lisa Miller
• Management of brain metastases in patients with HER2 positive breast cancer – a real world Australian experience - Cristina A Moldovan
• Factors associated with Fear of Cancer Recurrence in Breast and Colorectal Cancer Survivors - Sharon Nahm
• Perspectives on Physical Activity of Clinical Haematologists and Their Patients with Multiple Myeloma - Jennifer L Nicol
• A phase II cluster randomised controlled trial of a multi-component non-pharmacological intervention to prevent delirium for in-patients with advanced cancer (The PRESERVE pilot study)   - Jane Phillips
• Non-small cell lung cancer treated with radical radiotherapy or chemoradiation: a retrospective review at a regional cancer centre - Graham Pitson
• Bladder Cancer Treatment Patterns and Outcomes - Graham Pitson
• Improving Clinical Pathways of Oncology Patients in the Gippsland Region - Danielle Roscoe
• Is serum CA15-3 useful for assessing disease progression during systemic therapy in patients with metastatic breast cancer (MBC)? - Parameswar R Rachumalla
• Retrospective analysis of clinical characteristics and outcomes for patients enrolled in oncology phase 0 and Phase 1 clinical trials at Liverpool Cancer Therapy Centre - Parameswar R Rachumalla
• Real-world experience of nivolumab monotherapy in advanced non-small cell lung cancer (NSCLC): Retrospective analysis from a large tertiary centre - Ajay Raghunath
• Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients. - Megan ES Smith-Uffen
• Exploring the feasibility of rechallenging immunotherapy in lung and melanoma patients following a grade 3-4 immunotherapy-related adverse event.  - Laura Tam
• An overview of radiation necrosis in patients with brain metastases who received stereotactic radiosurgery with or without systemic treatment including immunotherapy at Sir Charles Gairdner Hospital. - Marianna Theodoulou
• Implementation of an Investigator Initiated Teletrial - Craig R Underhill
• Early signs of impaired gut function in patients with advanced cancer undergoing chemotherapy - Barbara S van der Meij
• Baseline clinical but not metabolic characteristics of cancer subjects dropping out of a clinical trial during chemotherapy are different from non-dropout subjects - Barbara S van der Meij
• Two-year efficacy and safety update from JAVELIN Merkel 200 part A: a registrational study of avelumab in metastatic Merkel cell carcinoma (mMCC) progressed on chemotherapy - Tom van Hagen
• A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck   - Louise Young
• Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results - Louise Young
• Lenvatinib+pembrolizumab in patients with advanced endometrial cancer: updated results - Louise Young
• Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma - Louise Young
• Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer - Louise Young
• Combination of microRNAs provide a synergistic effect on growth inhibition on MPM cells - Yuen Yee Cheng
• Population Based Analysis of Pleural Mesothelioma Patterns of Care and Outcomes in Regional Victoria - Graham Pitson
• A survey of the Western Australian Cancer Nurse Coordinators:  A comparison of attitudes and knowledge about smoking cessation interventions and nicotine dependence pre and post online training. - Caitlin Broderick
• Caring for the carer: empowering carers through educational workshop participation - Caroline Bulsara
• Adding colour to cancer: the art, science and education trifecta - Michelle Barrett
• Exploring the carer’s experience of looking after a person diagnosed with primary brain cancer: an exploration of carers’ experiences during nurse-led phone interviews for the intervention ‘Care-IS’ - Georgia KB Halkett
• What support are carers requiring over time during nurse-led support provided as part of the Care-IS study?: Preliminary Results - Georgia KB Halkett
• The complexity of diagnosing sarcoma in a timely manner - Georgia KB Halkett
• Ten years of collaborative learning and fostered networking for NSW Oncology and Haematology Pharmacists. - Aisling Kelly
• Thymic Hyperplasia following treatment with checkpoint inhibitors in a patient with stage IV Melanoma - Tiffany Foo
• A new way to talk about cancer – trialing a Cancer Pop up shop in Melbourne’s West - Sue M Merritt
• Building a cancer nursing research hub using formative evaluation design - Natasha Moloczij
• A Virtual Cancer Pharmacy Education Program for Pharmacists and Technicians Across an International, Multi-Site Organisation - Courtney Oar
• A collaborative approach to improving men’s health - Liz Simkiss
• The use of a brochure to enable CAM-with-chemotherapy patient education - Peter J Smith
• Oncology / Haematology 24 Hour Triage Rapid Assessment and Access Tool Kit - Aussie Style - Joan Thomas
• Are we overtreating Queensland cancer patients near end-of-life? - Neal Rawson
• A single centre experience of Pneumocystis jirovecii pneumonia (PJP) in patients with solid organ malignancy - Ciara Daly
• QOOL-Dash: converting data to accessible information for real-time monitoring of outcomes for patients reviewed at MDT - Neal Rawson
• Quality of care and quality of life for Queensland colorectal cancer patients - Neal Rawson
• Early on-therapy arthralgia predicts improved response and survival in advanced melanoma patients treated with vemurafenib and vemurafenib plus cobimetinib: A pooled analysis of clinical trial data - Ashley M Hopkins
• Febrile Neutropenia in a regional setting; Epidemiology and Microbiology Findings. - Tate Jacobson
• The rising incidence of neuroendocrine tumours - an epidemiological study of incidence and mortality of Neuroendocrine Neoplasms in Western Australia - Kim Kennedy
• Characteristics at presentation among prostate cancer patients diagnosed in the Loddon Mallee region of Victoria - Mwila Kabwe
• The Australian Mesothelioma Registry    - Thomas Watson
• Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews    - Marina van Leeuwen
• An audit of the time and completeness of diagnosis in primary advanced lung cancer at a regional public cancer centre without onsite bronchoscopy - Mark Flower
• Implementation of an integrated exercise physiology (EP) service within a tertiary cancer centre: experience from the Adem Crosby Centre, Sunshine Coast University Hospital (SCUH). - Curtis Forbes
• Improving the rate of documented patient consent for systemic therapy at a tertiary cancer care centre: a quality improvement project from the Sunshine Coast University Hospital. - Haakan Jakobsson
• Audit of patient & carer initiated telephone calls to a neuro-oncology cancer coordinator service - Anne King
• Patient and caregiver satisfaction with Cancer Council 13 11 20 Information and Support Services: an outstanding report-card on the provision of empathetic, person-centred supportive care - Katherine Lane
• Implementation of a centralised Charm governance framework across a national pharmacy organisation - Margaret Patterson
• 26-week results of the oncology pharmacist contribution to a pilot counselling service for oncology patients starting oral anticancer drugs (OADs) - Neil Reynolds
• Using Patient Reported Outcome Measures to inform cancer survivorship care and improve outcomes in a regional Victorian setting.   - Danielle Roscoe
• Access to phase 1 Clinical Trials Closer to Home-Integrating phase 1 trials in to a busy private practice - Adam Stoneley
• Outcomes of a new cancer rehabilitation and survivorship service in a rural hospital - Julie Symons
• Using the Optimal Care Pathway for People With Lung Cancer to conduct a gap analysis of patient care coordination requirements - Julia G Todd
• The WinPro Study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer. - Emma Carson
• ALT-TRACC: a registry-based randomised trial investigating alternating oxaliplatin and irinotecan doublets in treatment-naïve metastatic colorectal cancer - Evelien Rosens
• ATHENA (GOG-3020/ENGOT-ov45): a randomised, double-blind, placebo-controlled, phase 3 study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer - Jeffrey C Goh
• NUTMEG: A randomised Phase II study of Nivolumab and Temozolomide (TMZ) vs TMZ alone in elderly patients with newly diagnosed Glioblastoma (GBM): Trial in progress   - Merryn Hall
• Getting the dose right - Controversies in renal and hepatic dysfunction - Aisling Kelly
• A Phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-small cell lung cancer following progression on EGFR tyrosine kinase inhibitors (ILLUMINATE) - Antony Mersiades
• A Pilot Study of a Nurse and Pharmacist Led OTN (Ontario Telemedicine Network) Based Clinic for Management of Prostate Cancer Patients on Oral Therapy - Thomas McFarlane
• BR31: A phase 3, double blind, placebo controlled, randomized trial of adjuvant durvalumab in completely resected non-small cell lung cancer - Sue-Anne McLachlan
• Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV) - Antony Mersiades
• Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate) - Antony Mersiades
• PEARL: A randomised phase 3 trial of early referral to palliative care (PC) for patients with advanced thoracic malignancies. - Antony Mersiades
• A randomised open-label phase 2 trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after concurrent chemo-radiotherapy (STIMULI) - Antony Mersiades
• NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer (NSCLC), progressing after first or second line chemotherapy - Antony Mersiades
• “It takes a village” - Investigator-Initiated Clinical Trials in Melanoma and Non-Melanoma Skin Cancers (NMSCs) - Anne Cust
• Developing strategic and collaborative research partnerships: case-studies demonstrating strategies to identify additional research questions and priorities – the START trial experience. - Christine Paul
• NOX66 in combination with Palliative Radiotherapy in patients with mCRPC – a Phase 1 safety and dose finding study - Isabell Vocks

• Colorectal Surgery and Stoma Formation - Jennifer Ryan
• Stoma management, education and trouble shooting - Lisa M Richards
• Nutritional management of stomas - Sascha E McMeekin
• Sex, sleep, survival with a stoma: how people adjust and how we can support them - Haryana Dhillon

Panel discussion at end

• Up close and personal. How do we get the dose of cancer therapy right for every patient? - Christine V Carrington
• Anti-cancer therapy in the older patient - getting the dose right  - Michael Powell
• Sarcopenia significance in drug dosing – can it be embraced in the clinic? - Chris Lomma
• LFT derangement and cancer chemotherapy – guidelines and a black art - Michael Cain
• Electronic prescribing impact on chemotherapy errors – the good / the bad / the ugly - Daniel McKavanagh

• Lung cancer screening in Australia – what’s new and what’s recommended - Annette McWilliams
• Detection of early lung cancer- a radiology perspective - Stephen Melsom
• Patient Decision Aids - improving understanding and avoiding decisional conflict - David Manners
• Managing smoking in lung cancer patients: It's time to start the conversation. - Emma Dean
• Follow up and early detection after lung cancer treatment - what should we be doing?   - Fraser Brims

Panel discussion at the end

• “Real World” application of Nivolumab and the impact of performance status on outcomes of in patients with advanced non-small cell lung cancer (NSCLC) - Nazim Abbas
• Circular RNAs as novel biomarkers for detection of malignant pleural mesothelioma - Yuen Yee Cheng
• Low dose CT screen-detected malignant and non-malignant findings in a Western Australian asbestos-exposed cohort: results from the first five years of screening. - Edward JA Harris
• DREAM - A phase 2 trial of DuRvalumab with first line chEmotherApy in Mesothelioma: Final result - Peey-Sei Kok
• A Phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as Second of Third Line Therapy in Malignant Pleural Mesothelioma: final results of the FRAME study - Wei-Sen Lam
• Impact of altered radiotherapy treatment fractionation on acute skin toxicity in breast cancer - Ken Nguyen